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ABSTRACT
Objective: The purpose of this study was to evaluate the clinical behaviour, pathological
findings, survival and prognostic factors in young women in comparison to menopausal
women with epithelial ovarian malignancy. Methods: A retrospective analysis of 141
patients (67 for age below 40 years and 74 menopausal) treated between 1980 and 2000
was conducted. Results: Irrespective of the stage, the most common clinical presentation
was abdominal distension in both young (78%) and menopausal women (66%). In young
women, 52% presented at an early stage of the disease and in menopausal women this was
seen in 22% (p-value <0.05). The most common histological type of carcinoma in young
women was mucinous cystadenocarcinoma (36%) and in menopausal women, it was serous
cystadenocarcinoma (47%) (p<0.05).The overall 5-year survival rates in each group were
54% in young women and 41% in menopausal women. The 5-year survival rate appeared
to be influenced by the stage of disease and tumour debulking surgery from univariate
analysis in both young and menopausal women. In the final multivariate Cox proportional
hazard model analysis, the optimal tumour debulking surgery was a significant (0.25; 95%
CI (0.1-0.3) p <0.01) independent prognostic factor for survival probability in both young
and menopausal women Conclusion: There are limited reports in the literature comparing
the outcomes of younger and menopausal women with epithelial ovarian malignancy treated
by any gynaecology oncologist from a single academic institution. Our results showed that
the proportion of epithelial ovarian malignancy in young women was 30% from the total
identified numbers of patients treated for epithelial ovarian malignancy. Although different
types of carcinoma occurred in the young and menopausal women, the stage of the disease
at presentation and optimal debulking surgery are important prognostic factors to ensure
better survival rate.
Keywords: Epithelial ovarian malignancy, menopause, prognostic factors, survival
probability, young women
INTRODUCTION
Ovarian carcinoma is the leading cause of death from gynaecological malignancies in a
great majority of developed countries;[1] however, it is  low in the developing countries and
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Asia.[2] In a National Cancer Registry survey in 2002, ovarian cancer was the fourth most
common cancer among women in Peninsular Malaysia.[3] This accounted for 5.0% of the
total female cancers and the incidence was 7.4 per 100,000 population in Peninsular
Malaysia.[3] The age standardised incidence was 8.6 per 100,000 population and the disease
occurred most commonly amongst the Chinese with 10.4 per 100,000 population.[3] Malaysian
vital statistics in 1998 showed that there were 122 certified deaths due to ovarian cancer
which was 2.7% of all deaths from cancer.[4] Currently, there is very limited data about
epithelial ovarian malignancy in Malaysia especially in young women. Therefore this study
was conducted in order to evaluate the clinical behaviour, pathological findings, survival
and prognostic factors in young women as compared to menopausal women with epithelial
ovarian malignancy.
A retrospective study of young and menopausal patients treated in the University
Malaya Medical Centre (formerly known as University Hospital Kuala Lumpur) for epithelial
ovarian malignancy over the past 20 years was conducted to assess indicators that could
have an impact on overall survival in these two groups. Prognostic factors in patients with
epithelial ovarian malignancy need to be determined to accurately predict outcome and
tailor treatment according to individual risks and potential benefits. Several studies had
shown that clinico-pathological factors (tumour stage, histologic grade, residual disease
after primary surgery) had prognostic significance.[5,6,7]
The symptoms and clinical presentations in both groups of women might also give
information in evaluating a patient at presentation and to recommend a particular modality
of treatment, as well as to give patients a more realistic idea of their overall prognosis.
METHODS
Between 1January  1980 and 31December  2000, 258 women with epithelial ovarian malignancy
were treated in the Department of Gynaecology University of Malaya Medical Centre
(previously known as University Hospital Kuala Lumpur). The names of patients diagnosed
with epithelial ovarian malignancy were retrieved from the histopathological examination
(HPE) records in Department of Pathology University Malaya Medical Centre.  Eighty-five
patients were not evaluated in the study group as they were not menopausal (peri-
menopausal) and their age was above 40 years old because the objective of this study was
to evaluate the clinical behaviour, pathological findings, survival and prognostic factors in
young women (age 40 years and below) in comparison to menopausal women with epithelial
ovarian malignancy.
Menopause is the state in women’s life where there have no menstrual periods for 12
consecutive months and peri-menopause is the time in a woman’s life when physiological
changes occur that begin the transition to menopause.
Thirty-two patients’ clinical records could not be traced and they were excluded from
the study. The records could not be traced as all the clinical records of more than 10 years
in duration were destroyed by the hospital as the copies were kept in the form of microfilm
or compact discs (CD) and there was a possibility that the records were lost during this
process.
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A hundred forty-one (141) patients were left for inclusion in the final analysis. They
were studied by using their clinical records, that is,  various forms including the microfilms,
CD and histology request forms. Their presentation symptoms and clinical findings were
evaluated including the results of various investigations such as ultrasound and CT scan.
Their age at diagnosis, (International Federation of Gynecology and Obstetrics) (FIGO)
stage, and cytology of peritoneal fluid were defined. All operative and histo-pathological
findings were reviewed to classify tumour stages according to FIGO 1985.
The standard operative procedure included total abdominal hysterectomy, bilateral
salpingo-oophorectomy, omentectomy, appendicectomy and if judged necessary, segmental
bowel resections. Lymph node sampling and peritoneal biopsies were performed in the
presence of palpable abnormality. The size of the residual tumour was evaluated after
surgery. Initial cytoreductive surgery was classified as optimal if no residual tumour of less
than 1cm was left behind and suboptimal if residual tumour was more than 1cm. If a total
abdominal hysterectomy and bilateral salpingo-oophorectomy was not performed for stage
beyond 1c, the operation was considered suboptimal. A cystectomy or biopsy was also
considered as suboptimal surgery.
In borderline malignant tumours, unilateral salpingo-oophorectomy was considered as
optimal surgery.
Included in the study were patients (age 40 years below and menopausal) who had
initial surgery elsewhere and the diagnosis were confirmed by histopathological examination
and were subsequently managed at our centre.
The histolopathology was classified according to histologic type (serous, mucinous,
endometriod, clear cell, others (undifferentiated, unclassified, Brenner and mixed)  and
grading by carcinoma and borderline malignancy. The details of the histologic grade in
carcinoma cases were not evaluated as the detailed grading was not defined in most of the
HPE results. Serum CA 125 was not evaluated as the test was not done in all patients
especially from 1980 to 1990 as the technique was not well established. Adjuvant
chemotherapy was given to patients with FIGO stage 1c onwards.
Re-laparotomy was performed for suboptimal primary surgery, recurrence of cancer or
for second look- exploration.
Statistical Analysis
Survival, defined in years from primary surgery to date of death or to date of the last follow-
up, was evaluated on December 2002. All data were analysed using SPSS version 11.5.
Kaplan-Meier survival curves were calculated using univariate survival analysis. The log-
rank test was used to compare survival curves by obtaining a x2 value. Statistical significance
was considered when p<0.05. Cumulative survival curves were calculated separately for
age group, young and menopause, FIGO stage, peritoneal fluid cytology, histologic type
and grade, extent of primary cytoreductive surgery, size of residual tumours and
chemotherapy treatment for each group of patients. A multivariate proportional hazard
model (Cox) was used to test the prognostic value of various features.
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RESULTS
Patients’ Demographic Data
The patients’ mean age was 46 years (range 13-86); 67 patients were 40 years or less (range
13-40 years) and were included in young age criteria. Seventy- four were  menopausal. Of
the total identified numbers of patients (141 cases) treated for epithelial ovarian malignant
tumours,  47.5%  were young women while 32.7% were menopausal women.
Table 1 shows the clinical, stage and histo-pathological characteristics of the 141
patients with epithelial ovarian cancer and borderline malignancy.
Clinical Presentation
The symptoms observed in the young aged group and in the menopausal women were
almost similar. Irrespective of the disease stage, the most common presentation was
abdominal distension (78% in young and 66% in menopausal) and abdominal pain (30% in
young and 34% in menopausal) in both groups. However, this was not statistically significant
(p=0.1).
In young women, 39 patients (58%) had palpable mass per abdomen while for
menopausal women, it was   42 patients (56%). There were only 3 patients in young women
and 5 patients in menopausal women who were asymptomatic. All were in early stage (stage
I and II).
 In young women, 52% presented at an early stage of the disease, while in menopausal
women, 54% presented at advanced stage of the disease (p value <0.05).
Ascites was observed in 16.4% of young women; in   5.9% of these patients, the ascites
was massive. On the other hand, ascites was present in 36.9% of post-menopausal women;
48.1% was massive (p<0.05).
As shown in Table 1, pleural effusion was seen in 2% of young women compared to
13.6% in post menopausal women and all these patients were in the advanced stage of the
disease.
Histology
The most common histological type of carcinoma in young women was mucinous
cystadenocarcinoma (36%), whilst the most common type of carcinoma in post menopausal
women was serous cystadenocarcinoma (47%) (p<0.05).
Management
Figures 1 and 2 show the management modalities given to both young and menopausal
women. Optimal surgery was performed in 45 (67%) young  aged group of  patients and 49
(66%) in menopausal women. Sixteen out of 22 young aged women had suboptimal surgery
as the first surgery was not done in this centre. Eighteen of them needed to undergo a
second surgery in this centre to standardise or complete the procedure.
In menopausal women, 18 (52%) patients had suboptimal surgery as the first surgery
was not done in this centre. Eleven patients needed to undergo a second surgery to make
it complete. In 21of them, the  disease was very extensive.
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Table 1. Clinical, stage and histopathological characteristics of the 141 patients with epithelial
ovarian malignancy
Characteristics No. of patients (%) P-value
Age Young(n=67) Menopause(n=74) <0.001
Mean age (years) 31 59
40 years and below 67 (48)
40-50 years 13 (9)
Above 50 years 61 (44)
FIGO Stage 0.003
Stage I 35 (52) 16 (22)
Stage II 10 (15) 15 (21)
Stage III 15 (22) 25 (34)
Stage IV 7 (10) 16(20)
Histologic type 0.04
Serous 19 (28) 35 (47)
Mucinous 24 (36) 11 (15)
Endometriod 3 (5) 8 (11)
Clear cell 4 (6) 8 (11)
Borderline malignancy 13 (19) 8 (11)
Others 4(6) 2 (3)
Symptoms 0.5
Abd.distension 52 (78) 49 (66)
Abd.pain 20 (30) 26 (34)
Menstrual abnormality 9 (13) 9 (12)
Weight changes 10 (15) 17 (23)
Loss of appetite 6 (9) 11 (15)
Bowel symptoms 1 (1) 3 (7)
Urinary symptoms 2 (3) 5 (4)
Others 7 (10) 18 (23)
Asymptomatic 3 (4) 5 (7)
Signs at presentation 0.5
Palpable mass perabdomen 39 (58) 42 (56)
Palpable mass pervaginum 16 (24) 23 (32)
Bilateral masses 12 (18) 21 (29)
Unilateral mass 51 (76) 50 (67)
Size <10cm 21 (31) 24 (33)
Size >10cm 45 (67) 47 (63)
Ascites 11 (16) 27 (37)
Extraperitoneal spread 0.12
Pleural effusion 4 (2) 11 (14)
Liver 5 (8) 4 (7)
Multiple 1 (2) 2 (4)
Lymph node 1 (2) 3 (3)
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Adjuvant chemotherapy was given to 52 (78%) patients in the young aged group with
61% being given several types of combination chemotherapy drugs: 29% were given
cisplatinum, adriamycin and cyclophosphamide (the most common combination regime
used) and 17% were given single agent platinum based chemotherapy ( either carboplatin
or cisplatinum). Sixty four (88%) menopausal patients were given chemotherapy, 59% were
given different combination chemotherapy drugs, 45% were given cisplatinum, adriamycin
Figure 1. Young aged and menopausal women who underwent tumour debulking surgery
Figure 2. Young aged  and menopausal women given chemotherapy
80
70
60
50
40
30
20
10
0
Optimal Surgery Suboptimal Surgery
Surgery
Pe
rc
en
ta
ge Young
Menopause
Young
Menopause
100
80
70
60
50
40
30
20
10
0
Pe
rc
en
ta
ge
Chemotherapy
Chemotherapy Combine (PAC) Single (Platinum)
Malaysian Journal of Medicine and Health Sciences Vol. 6 (1) January 2010
 Comparison Between Young and Menopausal Women with Epithelial Ovarian Malignancy 25
and cyclophosphamide(the most common combination regime used), 14%   single platinum
based agent and 8% were given chorambucil only. Chemotherapy drugs were  given when
disease had exceeded stage 1c.
Survival Rate and Prognostic Factors
The overall 5-year survival rate was 54% in the young and 41% in menopausal women. The
5-year survival rates were 71, 50, 40% for patients with stages I, II and III respectively in
young women and the median survival period for stage IV young women was 6 months. The
5-year survival rates were 69, 47, 44% for patients with stages I, II and III respectively in
post-menopausal women and median survival for stage IV disease in these women was 1
year.
      Table 2 shows 5-year survival  rates according to prognostic indicators after univariate
analysis.  Age was not a significant prognostic indicator by univariate analysis for both
young and menopausal women, (p value=0.3). The 5-year survival was 54% in those below
40 years and 41% in menopausal women.
FIGO stage was a significant prognostic indicator by univariate analysis for both
young and menopausal women (p value< 0.05) but in this study, there was no difference in
5-year survival rates according to the stage of the disease when comparing these two
groups of women.
Peritoneal fluid cytology was a significant prognostic indicator in young aged women
(p value <0.05) but it was not a significant indicator in menopausal women. It was also not
a significant indicator when both groups were compared.
The extent of surgery was a significant indicator for both young and menopausal
women (p<0.05) but it was not a prognostic indicator when comparing the two groups of
women in this study.
The residual disease and adjuvant chemotherapy were significant prognostic factors
for menopausal women if the patients with borderline malignancy were excluded (p value<
0.05); but it was not significant for the young group.
Survival probability curves of the young aged and menopausal women are shown in
Figure 3. Overall survival for both groups of women was not statistically different (p=0.13)
but after 10 years the difference became statistically significant (p<0.001).
The survival probability curves according to the stage of the disease in the young
group and menopausal women are shown in Figures 4 and 5 respectively.  There was a
significant difference in survival probability according to the stage of disease in both
young and menopausal women but when comparing both, the survival probability according
to stage of the disease was not statistically significant in this study.
There was no statistical significance in survival probability when young and menopausal
women  were compared according to histology type. Table 2 shows the survival probability
according to the optimal debulking surgery in young  and menopausal women.
 There was a significant difference in survival probability according to optimal debulking
surgery in both young and menopausal women. However, in this study when comparing the
two groups, the overall survival probability was not statistically significant (p value=0.3)
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within 10 years but  became statistically significant only after a 10-year period (p < 0.01) as
shown in Figure 6.
The survival probability according to the type of chemotherapy given in young and
menopausal women was not statistically significant. A multivariate analysis was performed
to evaluate all factors that were significant in the univariate analysis.
In the final multivariate Cox proportional hazard model analysis, optimal tumour
debulking surgery was a significant (0.25; 95% CI (0.1-0.3) p <0.01) independent prognostic
factor in both young and menopausal women.
Table 2. Five-year survival rates according to prognostic indicators by univariate analysis
Prognostic indicators 5-year survival rate (%)
Young P-value Menopause P-value
Age 0.3
40 years and below 54
41-50 years 42
Above 50 years 41
FIGO Stage 0.003 0.003
Stage I 71 69
Stage II 50 47
Stage III 40 44
Stage IV 0 1
Peritoneal fluid cytology 0.029 0.16
Positive 36 38
Negative 73 57
Histologic type 0.13 0.6
Serous 47 50
Mucinous 50 36
Endometriod 100 50
Clear Cell 50 38
Extent of surgery 0.01 0.01
Optimal 60 51
Suboptimal/Non-optimal 40 20
Residual tumour 0.159 0.05
Negative 60 52
<1cm 33 33
>1cm 38 19
Chemotherapy 0.9 0.05
Yes 54 45
No 53 11
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DISCUSSION
Epithelial ovarian malignancy had been extensively studied in developed countries from
the epidemiological point of view, clinical presentation, histopathological examination and
prognostic factors related to 5-year survival rates. [8,9,10]  Similar to many other studies10,11,12,
this study also showed that ovarian malignancy was a disease of perimenopausal and
Figure 3. Survival probability in epithelial ovarian malignancy in young and menopausal women
Figure 4.  Survival probability according to stage of disease in young aged  women
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menopausal women (70% of identified cases belonged to this group). The epithelial ovarian
malignancies rarely occurred before puberty and were uncommon prior to age 40.[13] Jensen
& Norris, reporting on 353 cases of benign and malignant ovarian neoplasms’ in females
under age 20, found no epithelial malignancies among 54 neoplasms in the 0-9 years age
group, 1 among 82 neoplasms in the 10 to 14 years age group, and only 7 among 217
Figure 5.  Survival probability according to stage of disease in menopausal women
Figure 6. Survival probability of the young aged group and menopausal women according to
optimal surgery
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neoplasms in the 15 to 19 year group. Five of the eight malignant epithelial ovarian tumours
were classified as cystadenomas of low malignant potential (borderline malignant tumours).[14]
In this study, 40/141 patients (28%) were less than 40 years old at diagnosis, making
epithelial ovarian carcinoma not uncommon in young patients in our society. The initial
presentation at diagnosis was similar in the young and menopausal patients. Most of them
presented with abdominal distension (78% in young and 66% in menopausal) and with
palpable masses per abdomen (58% in the young and 56% in those menopausal). Only 6%
were asymptomatic (3 patients in young aged group and 5 patients in menopausal group).
Buka & MacFarlane reported that 66% of 223 cases had palpable ovarian masses, 18% had
masses with ascites, 9% had ascites without a palpable mass and 18% had pelvic nodules.[15]
In this study most young aged patients presented at an early stage of the disease
(52%) but the menopausal patients presented at an advanced stage (54%). This was probably
due to the asymptomatic nature of the disease in its early stage in menopausal women.
Several investigators documented that younger women with ovarian carcinoma had a better
prognosis than older women. Smedley & Sikora, in  reviewing of 2305 ovarian cancer patients
in the United Kingdom, found that the 5-year survival rate for women aged 15 to 35 years
was approximately 60%, versus 30% for older women.[16] In this study, the 5-year survival
rate for young women was 54% and 41% in menopausal women. The age of patients was not
a significant prognostic factor and optimal debulking surgery was an independent prognostic
factor in both young and menopausal patients in this study.
FIGO stage was a prognostic indicator recognised by most authors, occasionally
independent from the results of surgery and the type of chemotherapy.[17,18]  In this study it
was a significant prognostic factor by univariate analysis but not by multivariate analysis.
Most studies reported a low prognostic value for histologic type, probably due to a
bias in analysing small samples such as the case of this study. However; serous and
undifferentiated carcinoma tend classically to decrease survival. [5,6] In this study, the 5-
year survival rates for serous cystadenocarcinoma were 50% and 47% in menopausal women
and young aged group respectively. The prognostic significance of grade was demonstrated
by several clinical studies in the 1980s.[5,6]  However, grading has not been accepted
enthusiastically by pathologists, because no standard is easily reproducible, and objective
classification exist. Furthermore, after adjusting for FIGO stage and histologic type, the
grade did not appear to be an independent factor in some recent multivariate analyses.[18,19]
In University Malaya Medical Centre, grading was not defined in most of the
histopathological examination. In this study, 69% of the histopathological examinations,
were without any grading resulting in histologic grade details being not analysed as a
prognostic indicator. Patients with borderline malignancy had a 100% five-year survival
rate in young aged group and 75% in menopausal women.
The role of debulking surgery in the management of stage III epithelial ovarian cancer
has been well established.[20,21,22] In this study, the extent of surgery was a significant
prognostic factor in both menopausal and young aged patients.  Residual disease at the
end of surgery and adjuvant chemotherapy were significant prognostic factors in menopausal
women but not in the young as most of the young patients presented at an early stage of
the disease. A re-laparotomy for tumour debulking in the advanced stage of disease or in
patients who had suboptimal surgery due to improper staging improved the 5-year survival
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rate in both young and menopausal women. A meta-analysis of prognostic factors has been
conducted to identify the different variables cited in prospective and randomised studies.[10]
In this study, 77.6% of young and 87.6% of menopausal patients had received
chemotherapy. Patients who were not treated by adjuvant chemotherapy belonged either to
a very bad prognostic group with short-term death or to a very good prognosis such as
stage Ia or borderline malignancy tumour where adjuvant treatment was not indicated.
Chemotherapy including cisplatin as initial treatment with a residual tumour mass of
less than 2 cm prior to therapy was found to be the only factors of prognostic relevance in
the multivariate model.[10] However, the impact of maximum cytoreductive surgery in
comparison with platinum-based combination chemotherapy has become controversial. In
a meta-analysis of 58 suitable studies encompassing 6962 patients, maximum cytoreductive
surgery was associated with only a small improvement in median survival time (+4.1%,95%
CI (-0.6 to 9.1%), P=0.089), while platinum-containing chemotherapy improved median
survival time substantially (+53%, 95% CI (35 to 73%), P<0.001). [23] Progress in chemotherapy
has certainly contributed to the increased survival rate observed during the past 20 years,
an improvement of 20% between 1978 and 1989 in women under 65.[24,25]
The limitation of this study was the inability to get all the information of patients in the
earlier phase as their original case notes/records had already been destroyed. The clinical
summary given in the histopathological examination request forms was inadequate. It would
have been useful if the peri-menopausal women were also evaluated for comparison as the
majority of epithelial ovarian malignancy occured in this age group. However, in this study,
this group was not evaluated due to difficulty in retrieving clinical information. A prospective
study should be continued for the next few years in the gynaecology oncology centre to
obtain clinical and management details without missing relevant data.
CONCLUSION
There are limited reports in the literature comparing the outcomes of younger and menopausal
women with epithelial ovarian malignancy treated by any gynaecology oncologist from a
single academic institution. Our results showed that the proportion of epithelial ovarian
malignancies in young aged women was 30% from the total identified number of patients
(141 identifiable cases) treated for epithelial ovarian malignancy. The symptoms and signs
at presentation were similar in menopausal women but the young aged women presented at
an early stage of disease. Although different types of carcinoma occurred in the young
aged and menopausal women, the stage of the disease at presentation and optimal debulking
surgery were two important prognostic factors (not the patient’s age at diagnosis) to ensure
better survival rate of the patients.
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